Y. Aras Et Al. , "Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro," NEUROLOGICAL RESEARCH , vol.38, no.9, pp.766-774, 2016
Aras, Y. Et Al. 2016. Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro. NEUROLOGICAL RESEARCH , vol.38, no.9 , 766-774.
Aras, Y., Erguven, M., Aktas, E., Yazihan, N., & Bilir, A., (2016). Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro. NEUROLOGICAL RESEARCH , vol.38, no.9, 766-774.
Aras, Yavuz Et Al. "Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro," NEUROLOGICAL RESEARCH , vol.38, no.9, 766-774, 2016
Aras, Yavuz Et Al. "Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro." NEUROLOGICAL RESEARCH , vol.38, no.9, pp.766-774, 2016
Aras, Y. Et Al. (2016) . "Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro." NEUROLOGICAL RESEARCH , vol.38, no.9, pp.766-774.
@article{article, author={Yavuz ARAS Et Al. }, title={Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro}, journal={NEUROLOGICAL RESEARCH}, year=2016, pages={766-774} }